68Ga-DOTATOC PET/CT在复发性肾细胞癌中的临床价值
该回顾性研究分析了25例肾细胞癌术后患者,评估68Ga-DOTATOC PET/CT对复发或转移灶的检出能力。基于患者和病灶的灵敏度分别为88%(22/25)和87%(66/76)。
要点
- 68Ga-DOTATOC PET/CT对透明细胞肾细胞癌复发灶检出灵敏度高。
- DOTATOC与FDG PET/CT在肾细胞癌复发病灶检出中具有互补价值。
- 乳头状肾细胞癌病灶可能仅被FDG-PET/CT检出。
核心结论
- 68Ga-DOTATOC PET/CT有助于检出透明细胞肾细胞癌患者的复发灶。
- DOTATOC-PET/CT与FDG-PET/CT被认为具有互补作用。
研究设计与样本
- 回顾性分析25例肾细胞癌术后连续患者(23例透明细胞、1例乳头状、1例未分类)的DOTATOC-PET/CT扫描。
- 以组织病理学或临床随访为参考标准,按患者和病灶计算检出率。
主要发现
- 最终诊断确认76个复发或转移病灶,其中22例患者的66个病灶DOTATOC-PET/CT阳性。
- 基于患者的灵敏度为88%(22/25),基于病灶的灵敏度为87%(66/76)。
- 8个病灶仅由DOTATOC检出,但4个乳头状肾细胞癌病灶仅由FDG检出。
临床怎么用
- 对于透明细胞肾细胞癌术后怀疑复发的患者,可考虑使用68Ga-DOTATOC PET/CT进行再分期。
- DOTATOC-PET/CT与FDG-PET/CT联合应用可能提高复发灶检出率。
局限性
- 本研究为回顾性研究,样本量较小(25例患者)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Positron emission tomography (PET)/computed tomography (CT) with 68Ga-labelled 1,4,7,10-tetraazacyclododecane-N,N',N″,N″'-tetraacetic acid-D-Phe1-Tyr3-octreotide (DOTATOC) has been accepted as a diagnostic imaging tool especially for patients with neuroendocrine tumours. However, its clinical usefulness for restaging of renal cell carcinoma (RCC) has not been fully investigated. This retrospective study was performed to elucidate the clinical value of PET/CT using 68Ga-DOTATOC in patients with known or suspected recurrent RCC. METHODS: We analysed 25 consecutive patients who underwent DOTATOC-PET/CT scans after surgery for RCC (23 clear cell, 1 papillary, 1 unclassified). PET/CT findings were reviewed and the detection rate was calculated on a patient and lesion basis. The detectability was compared in patients who also underwent PET/CT scans with 18F-fluorodeoxyglucose (FDG). Histopathological findings or clinical follow-up were used as the reference standard. RESULTS: Based on the final diagnosis, 76 recurrent or metastatic lesions were confirmed in this population. Of these lesions, 66 lesions in 22 patients were positive by DOTATOC-PET/CT. The patient-based and lesion-based sensitivity was 88% (22/25) and 87% (66/76), respectively. Twelve patients underwent both DOTATOC-PET/CT and FDG-PET/CT. The lesion-based sensitivity of DOTATOC was 74% (20/27), while that of FDG was 59% (16/27). Eight lesions were identified only by DOTATOC, but four lesions from papillary RCC were detected only by FDG. CONCLUSION: Our data indicate that DOTATOC-PET/CT would be useful for detecting recurrent foci in patients with clear cell RCC. DOTATOC-PET/CT and FDG-PET/CT are considered to have complementary roles.
引用
- Nakamoto Y, Ishimori T, Shimizu Y, et al. Clinical utility of 68Ga-DOTATOC positron emission tomography/computed tomography for recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019. PMID: 30847538. doi:10.1007/s00259-019-04298-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。